This interpretation reconciles the complex observations from the EAE model suggesting a key role for CCR2 – CCL2 in the development of inflammatory lesions, and from MS suggesting a low expression of CCR2 and increased expression of CCL2 in active plaques, but a decreased CCL2 level in the CSF. This evidence concerns the gene CCR2 and myeloid sarcoma.